Cart
sales@molnova.com
Sorafenib-d3
CAS No. 1130115-44-4
Sorafenib-d3( Sorafenib (D3) | Bay 43-9006 (D3) )
Catalog No. M26821 CAS No. 1130115-44-4
Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 205 | In Stock |
|
| 10MG | 357 | In Stock |
|
| 25MG | 597 | In Stock |
|
| 50MG | 843 | In Stock |
|
| 100MG | 1134 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSorafenib-d3
-
NoteResearch use only, not for human use.
-
Brief DescriptionSorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
-
DescriptionSorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
-
In Vitro——
-
In Vivo——
-
SynonymsSorafenib (D3) | Bay 43-9006 (D3)
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorTGFβ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1130115-44-4
-
Formula Weight467.84
-
Molecular FormulaC21H16ClF3N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (213.75 mM)
-
SMILESO(C=1C=C(C(NC([2H])([2H])[2H])=O)N=CC1)C2=CC=C(NC(NC3=CC(C(F)(F)F)=C(Cl)C=C3)=O)C=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bowen C, et al. Mitochondrial-related effects of pentabromophenol, tetrabromobisphenol A, and triphenyl phosphate on murine BV-2 microglia cells. Chemosphere. 2020 Sep;255:126919.
molnova catalog
related products
-
TBAP-001
TBAP-001 is a RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay and an IC50 of 18 nM in Cell-Based Phosho-ERK Assay.
-
BI 882370
BI 882370 is a highly potent, selective, orally active RAF inhibitor with IC50 of 0.4, 0.8 and 0.6 nM for BRAF V600E, BRAF WT and CRAF, respectively.
-
Compound 23
Compound 23 selectively induces degradation of BRAF-V600E but not wildtype BRAF.
